Maravai Lifesciences Holdings (MRVI) Current Deferred Revenue (2020 - 2025)

Maravai Lifesciences Holdings' Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $1.6 million for Q2 2025.

• On a quarterly basis, Current Deferred Revenue fell 23.63% year-over-year to $1.6 million in Q2 2025; TTM through Jun 2025 was $1.6 million, a 23.63% decrease from a year earlier, with the FY2024 full-year figure at $2.4 million, down 56.82% from the prior year.
• Current Deferred Revenue retreated to $1.6 million in Q2 2025 per MRVI's latest filing, from $2.8 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $120.7 million in Q1 2021 and bottomed at $1.6 million in Q2 2025.
• The 5-year median for Current Deferred Revenue is $4.8 million (2022), against an average of $20.2 million.
• Across the five-year window, Current Deferred Revenue slumped 95.61% in 2022 and increased 24.71% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $12.6 million in 2021, then tumbled by 61.9% to $4.8 million in 2022, then advanced by 14.58% to $5.5 million in 2023, then sank by 56.82% to $2.4 million in 2024, then slumped by 30.99% to $1.6 million in 2025.
• Per Business Quant, the three latest MRVI Current Deferred Revenue figures stand at $1.6 million (Q2 2025), $2.8 million (Q1 2025), and $2.4 million (Q4 2024).